Unexpected Antiviral Activity of Spironolactone

Update item information
Identifier unexpected-antiviral-activity-spironolactone
Title Unexpected Antiviral Activity of Spironolactone
Creator Swaminathan, S.; Verma, D.; Internal Medicine; School of Medicine; University of Utah Health
Subject Diffusion of Innovation; Herpesvirus 4, Human; Spironolactone; Transcription, Genetic; Viral Transcription; Transcription Initiation Site; Xeroderma Pigmentosum; SM protein, Human herpesvirus 4; Antiviral Agents; RNA Polymerase II; Knowledge Discovery
Keyword Immunology, Inflammation, Infectious Disease
Image Caption A model of how the Epstein-Barr virus (EBV) uses xeroderma pigmentosum group B-complementing protein(XPB) to facilitate viral RNA synthesis by (1) initiating transcription from a viral gene promoter at the transcriptional start site (TSS) via RNA polymerase II (RNAPII) (viral pre-initiation complex (vPIC) required for viral transcription also present), after which; (2) SM binds to newly transcribed RNA, and then; (3) recruits XPB to facilitate elongation of the RNA transcript.
Description Epstein-Barr virus (EBV) is a human herpesvirus associated with clinical infections and several types of malignancies. Sankar Swaminathan, MD, and colleagues showed that a hypertension/heart failure drug, spironolactone, also has anti-EBV effects. The antiviral activity of spironolactone is not related to its mineralocorticoid blocking activity relevant to hypertension/heart disease, but, instead, to its ability to inhibit the function of a protein SM that is essential for EBV replication. In the first demonstration of its kind, this research also showed that EBV SM protein activates viral gene transcription by utilizing xeroderma pigmentosum group B-complementing protein (XPB) as a cofactor. This is the first demonstration that XPB is utilized as an essential cofactor by a human herpesvirus. The XPB protein is degraded by spironolactone. Therefore, XPB may be a useful therapeutic target to control EBV and other human herpesviruses. Further, because the SM protein acts at stages of the viral life cycle different from those targeted by available therapies, these observations pave the way for the development of novel anti-EBV drugs that address emerging drug resistance and toxicity problems.
Relation is Part of 2020
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Date Digital 2021
Date 2020
Type Image
Format image/jpeg
Rights Management Copyright © 2021, University of Utah, All Rights Reserved
Language eng
ARK ark:/87278/s61g6m7h
References 1.) Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Verma D, Thompson J, Swaminathan S. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):3609. Published online 2016 Mar 14. doi: 10.1073/pnas.1523686113. 2.) Epstein-Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters. Verma D, Church TM, Swaminathan S. Proc Natl Acad Sci U S A. 2020 June 9;117(23):13044. doi: 10.1 /pnas.2000625117
Setname ehsl_50disc
ID 1703481
Reference URL https://collections.lib.utah.edu/ark:/87278/s61g6m7h